Cancer is a genetic disease caused by mutations and chromosomal abnormalities which contribute to uncontrolled cell growth. In addition, cancer cells can rapidly respond to conventional and targeted therapies by accumulating novel and often specific genetic lesions leading to acquired drug resistance and relapsing disease. In chronic lymphocytic leukemia (CLL), however, diverse chromosomal aberrations often occur. In many cases, improper repair of DNA double strand breaks (DSBs) is a major source for genomic abnormalities. Therefore, this study examined the repair of DNA DSBs by non-homologous end joining (NHEJ) in CLL by performing plasmid based repair assays in primary CLL cells and normal B cells, isolated from patients, as well as TALEN/Cas9-induced chromosomal deletions in the CLL cell line Mec1. It is demonstrated that DNA repair is aberrant in CLL cells, featuring perturbed DNA break structure preference with efficient joining of noncohesive ends and more deletions at repair junctions. In addition, increased microhomology-mediated end joining (MMEJ) of DNA substrates was observed in CLL together with increased expression of MMEJ-specific repair factors. In summary, these data identify major differences in DNA repair efficiency between CLL cells and normal B cells isolated from patients.
Introduction
Whole genome sequencing revealed the presence of numerous clonal and subclonal somatic mutations as well as somatic rearrangements in cancer genomes(1-3). Upon cancer therapy, subclonal refractory cells harboring acquired novel chromosomal aberrations or gene mutations can expand and may thus contribute to therapy resistance and disease relapse(4-6). A major source for chromosomal rearrangements are DNA double strand breaks (DSBs). DSBs occur constantly during the lifetime of any cell and are normally repaired. However, aberrant repair of DSBs can lead to mis-joining of distant DNA ends, generating deletions, inversions or complex rearrangements of chromosomes(7;8). DSBs are repaired by two major pathways, which are homologous recombination (HR) and nonhomologous end joining (NHEJ). HR utilizes the sister chromatide as template for repairing DSBs and is thus primarily confined to S/G2/M phase of the cell cycle, whereas NHEJ simply rejoins two DNA ends and, hence, is the main repair pathway for G1 or G0 arrested cells(7).
For NHEJ, a classical and an alternative pathway are described, termed c-NHEJ and a-NHEJ, respectively. While c-NHEJ is dependent on recognition of DNA ends by XRCC5, XRCC6 and DNA-PKc and ligation by DNA Ligase 4 (Lig4)/XRCC4, a-NHEJ is carried out independently of Lig4 and can probably be executed by a diverse set of factors, including different DNA polymerases (δ, θ), DNA nucleases (ERCC1-XPF) and ligases (Lig1, Lig3/XRCC1)(9-11). As a-NHEJ is frequently associated with short microhomologies (MH) at the site of DNA junctions, a-NHEJ is also termed MH mediated end joining (MMEJ). many of the hematological malignancies show typical entity-specific chromosomal abnormalities(15), there is no specific aberration defining CLL. Instead, in addition to more common chromosomal abnormalities like del(17p), del(11q), del(13q) and Tri12, conventional cytogenetics as well as novel whole genome sequencing approaches revealed a complex set of different chromsomal aberrations in CLL, with CLL-UM samples showing a slight increase in the number of aberrations(3;5;6;16-19).
In this study, we asked whether the frequent occurrence of chromosomal abnormalities is associated with an inherently aberrant DNA DSB repair in CLL. To test this, we analysed DNA DSB repair in primary CLL cells compared to B cells from healthy controls by assessing in vivo repair of artificial DNA substrates carrying diverse DNA break structures using next generation sequencing of repair junctions. These results were corroborated by analyzing the induction of a large chromosomal deletion using TALEN (Transcription activator-like effector nuclease)/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9) endonucleases (20) . Our data show that DNA end joining is less precise and more promiscuous in CLL with a bias towards microhomologies as well as towards joining of incompatible DNA ends, likely due to increased expression levels of Lig1 and XRCC1.
Materials and Methods

Preparation of plasmid repair substrates and transfection of cells.
Plasmids were generated by cloning synthesized inserts (MWG eurofins) into pAX plasmids (sequence shown in supplementary Fig S1) . Plasmids were linearized using the respective restriction enzymes (Fermentas), gel purified (Qiagen) and transfected into 293 cells (genejuice, Novagen) and primary B and CLL cells using nucleofection (Amaxa, Lonza). 72h post transfection, cells were harvested and DNA was isolated (Qiagen). Repaired substrates were PCR amplified using high fidelity Phusion polymerase (Biozym) and tagged 3AOX/5AOX primers (3AOX 5'-GCA AAT GGC ATT CTG ACA TCC-3'; 5AOX 5'-GAC TGG TTC CAA TTG ACA AGC-3'). PCR products were pooled and sequenced on the miseq platform (Illumina).
pmCherry was generated by cloning the PCR amplified coding region of mCherry (RG1081 5'-CGCGGGCCCGGGATCGCCACCATGGTGAGCAAGGGCGAGG-3' and RG1082 5'-TCTAGAGTCGCGGCC TACTTGTACAGCTCGTCC-3') into BamHI/NotI digested pEGFP-N1 (clontech) using In-Fusion HD cloning (Clontech). Plasmids pGFP-1 and pGFP-2 were generated by introducing a BsmBI or an EcoRV site at position nt 137 and nt 141 of the GFP coding region using PCR-based mutagenesis of the pEGFP-N1 plasmid. Plasmids were digested using BsmBI/MfeI (pGFP-1) and EcoRV/PstI (pGFP-2) and gel extracted prior transfection together with pmCherry into 293 cells using genejuice transfection reagent or nucleofection (Amaxa) as indicated. 6h before transfection, cells were incubated with highly specific inhibitors for Lig1/3 (L67), DNA-PKc (NU7441) and PARP (Olaparib, all from Selleckchem). After transfection, cells were incubated for further 2 days in presence of inhibitors prior analysis for mCherry/GFP expression using flow cytometry (FC500, Beckman Coulter).
Gene expression analysis
RNA was isolated from purified CLL samples and B cells from healthy controls using high pure RNA isolation kit including DNase digestion (Roche). The same CLL samples as used for plasmid repair assays was used for RNA isolation. First strand cDNA was generated using iScript (bio-rad). Gene expression levels in CLL, Mec1 and B cells were determined using taqman assays (ThermoFisher) for Lig1 (Hs01553527_m1), XRCC1 (Hs00959834_m1), PARP1 (Hs00242302_m1) with 18S rRNA as controls (Hs99999901_s1).
Research. 
Nuclease induced chromosomal deletions
Cas9 constructs specific for chr17 position 41,621,709 (KRT17 locus) were generated by cloning annealed oligos (RG1087 5'-ccggGGTGGGTGGTGAGATCAATG-3' and RG1088 5'-aaacCATTGATCTCACCACCCACC-3') into prelinearized pGuide-it-ZsGreen1 Vector (Clontech).
TALENs specific for chr17 position 40,819,524-40,819,583 (KRT10 locus) were kindly provided by Oliver March (Paracelsus Private Medical University Salzburg, Austria). The CLL cell line Mec1 (21) was incubated for 6h in RPMI medium supplemented with or without 30µM Lig1/3 inhibitor L67 followed by Amaxa nucleofection (Lonza) with TALEN/Cas9 constructs. Cells were kept on RPMI medium supplemented with or without L67 for further 2 days prior sorting of GFP positive cells on a FACS AriaIII (Beckton Dickinson; purity ≥94.1% GFP+) and isolation of DNA (Qiagen). Chromosomal deletions were PCR amplified using Phusion polymerase and specific primers (RG1142 5'-TGGCATCTTCTTGGGGTTTA-3' and RG1143 5'-CCACATCCCCTTTTTCCATA-3'). For amplicon sequencing, PCR products from 50ng template DNA from two independent experiments were pooled and sent for sequencing on the miseq platform (Illumina). For quantification of chromosomal deletions, input DNA from cells descending from four independent experiments was titrated from 25ng to 1.56ng and subjected to PCR using primers RG1142/RG1143 and HotStar Taq DNA polymerase (Qiagen). For cell cycle analysis, purified B and CLL cells were stained using CD5-FITC (clone: UCHT2; eBioscience) and CD19-PE/Cy7 (clone: SJ25C1; eBioscience) antibodies in PBS at room temperature. Cells were resuspended in prewarmed RPMI without Phenol-Red and stained with vybrant cell cycle dye (Vybrant® DyeCycle™ Violet Stain, V35003; ThermoFisher) for 1h at 37°C followed by immediate analysis by flow cytometry (Gallios, Beckman Coulter) Sequence analysis and Bioinformatics.
Cells and cell lines
Paired end fastq files were acquired by eurofins genomics and GATC-Biotech (Germany).
Raw reads were trimmed and selected for paired reads using Trimmomatic v0.33 (23) we decided to use the unique 6 bp stretch 3' of the conserved primer binding sites for mapping. Analyses of read length, frequency and sequence were performed using custom BASH and PERL scripts, which can be provided upon request. Sequence alignment for detection of deletions was perfomed using MAFFT alignment program (25) . Circos plots were created in R using the circlize package (v0.3.8). All other graphs were created in Graph Pad Prism 5 and Inkscape v0.91.
Results
Next generation sequencing-assay for detecting repair of different DNA end structures
To test the efficiency of DSB repair, we set up a plasmid based repair assay, consisting of a pool of nine plasmids which harbor individual 350bp inserts flanked by conserved primer binding sites ( Fig 1A, supplementary Fig S1) . Upon digestion with respective restriction enzymes, the individual plasmids yield defined DNA break structures ranging from blunt ends with and without a 6bp microhomology to cohesive and non-cohesive 3' and 5' protruding ends with 4 nt overhangs ( Fig 1B) . Upon transfection into primary cells, the linear 
DSB repair favors incompatible DNA ends in CLL cells
To detect aberrant DSB repair in CLL cells, we used our pool of linearized plasmid substrates to nucleofect primary CLL cells (CLL-Mut n=4, CLL-UM n=3; patient details shown in supplementary table S2) and B cells from healthy controls (n=3). Three days after nucleofection, we isolated DNA and PCR amplified repair junctions from each sample.
Notably, we observed repaired substrates immediately after nucleofection in some CLL samples, which is in line with published data on rapid end joining of DNA ends ( Fig 1C) (26) .
Upon NGS of pooled amplicons, we obtained a total of 2.676,354 reads, ranging from 96,000 to 587,418 reads for all samples (Fig 1D) . Fig 2C and supplementary table S4 ).
More end resection occurs during DSB repair in CLL cells
We next aimed at determining differences in the occurrence of deletions at repair junctions between CLL and B cells, resulting from joining of end resected DNA ends. Therefore, we first identified the most frequent repair junction for CLL-Mut, CLL-UM, and B cells for all individual intramolecular repair events and mapped all shorter sequences to the most frequent consensus. We thereby found that the most frequent repair junctions of the nine DNA substrates were the same within each sample group (CLL-Mut, CLL-UM, B cells; Fig 3A) : blunt ends -irrespective of a 6bp microhomology -and cohesive 3' and 5' ends were preferably simply rejoined, whereas 1bp microhomologies were preferentially used when repairing non-cohesive 3' (substrate #3, Fig 3A) and 5' overhangs (substrate #5, Fig 3A) .
Incompatible 3'-5' overhangs (substrate #7), 3' overhang/blunt and 5' overhang/blunt ends (substrate #8 and #9) were preferentially joined and the ssDNA gaps filled up (Fig 3A) .
We next graphically illustrated the occurrence of deletions at repair joints which we discerned by NGS. In all cases, deletions clustered around the repair junction of the most frequent consensus sequences (Fig 3B) . By comparing the median numbers of resected bases (deletions) at repair junctions, we found that deletions were significantly more Wilcoxon rank sum test with continuity correction; Fig 3C) .
DNA DSB repair is skewed towards MMEJ in CLL
Upon analyzing the sequences harboring deletions at the repair junction, we observed a high incidence of 1-9bp microhomologies flanking the deleted region irrespective of the sample group (CLL and B cells; supplementary Fig S2) . As these microhomologies could at least in part derive from repair by MMEJ and as deletions were occurring at higher incidence in CLL (Fig 3) , this prompted us to test whether the MMEJ pathway is generally more active in CLL compared to B cells. To this end, we more thoroughly analysed repair junctions of substrate #2, featuring a 6bp microhomology at both DNA ends. As already shown by Verkaik and coworkers using a similar approach, repair by the MMEJ pathway leads to deletion of one of the two 6bp microhomologies, whereas repair by c-NHEJ results in direct joining of the DNA ends, yielding a direct repeat of 6bp within the repair junction (27) . 
Next, we tested whether CLL-specific efficient joining of incompatible DNA ends was solely dependent on MH-based repair of end-resected substrates. To test this, we only considered repair junctions mapping to the most frequently occurring sequence of a particular repaired substrate and calculated their relative frequencies, without considering repair of resected substrates. Thereby we found that again various incompatible DNA ends were more efficiently repaired in CLL cells compared to B cells, leading to a total of 12 junctions which were significantly overrepresented in CLL samples (Fig 4B and supplementary table S5 ).
Again, none of the repair events were significantly overrepresented in B cells compared to CLL cells (Fig 4B and supplementary table S5 ). Though 7 out of these 12 junctions revealed short microhomologies (1 to 5 nt, supplementary table S5), 5 of these junctions were generated by direct intermolecular joining of 3'-5' overhangs or 5' overhang-blunt ends, implying that incompatible DNA ends were more efficiently joined in CLL cells also independent from terminal microhomologies (Fig 4C, supplementary table S5 ).
To elucidate the underlying mechanism for biased DSB DNA repair in CLL cells, we first analysed cell cycle stages in CLL and B cells (supplementary Fig S3) . However, both CLL samples as well as B cells were mostly in G1 phase (range 90.2-95.2% for CLL; 87.5-97.5% for B cells) with no apparent cell cycle differences (supplementary Fig S3) . We next examined expression levels of key factors involved in MMEJ and c-NHEJ in CLL and B cells (9). By extracting data from Haslinger and coworkers(28) using the oncomine database (29) (www.oncomine.org), we found that several genes, including PARP1, XRCC1 (forming a complex with Lig3) and Lig1, which all are involved in MMEJ were significantly upregulated in CLL compared to normal B cells (Fig 5A) . In contrast, within the set of factors involved in c-NHEJ, only DNA-PKcs (PRKDC) and PARP3 showed a slight but significant overexpression in CLL and none of the factors examined showed downregulation in CLL (Fig 5A) 
expression of MMEJ factors in our CLL samples, we performed realtime RT-PCRs.
Consistently, Lig1, XRCC1 and PARP1 were all higher expressed in CLL samples compared to B cells from healthy donors (supplementary Fig S4) . As increased expression levels of MMEJspecific factors could likely be causative for our observed bias towards MMEJ in CLL cells, we finally wanted to test whether PARP1, Lig1 or Lig3/XRCC1 could also contribute to MHindependent joining of incompatible ends, in particular intermolecular joining of 5' overhangs with blunt ends which we particularily observed to be increased in CLL samples (Fig 4B, C) . Therefore, we performed a 293 based assay for direct joining of two GFP-based reporter constructs (pGFP-1 and pGFP-2) which encode a functional GFP protein only upon intermolecular direct joining of pGFP-1 (encoding the N-terminal portion of GFP with a 4 nt 5' overhang) and pGFP-2 (encoding the C-terminal portion of GFP starting with a blunt end) (Fig 5B) . GFP expression based on direct joining of pGFP-1/pGFP-2 was analysed in presence of specific inhibitors targeting PARP (Olaparib), Lig1/3 (L67), and DNA-PKc (NU7441) as control. To normalize for transfection efficiencies, we cotransfected a plasmid encoding mCherry (pmCherry). As expected, direct repair of the GFP plasmids was strongly impeded by inhibition of DNA-PKcs, which are central to c-NHEJ. To a lesser extent also inhibition of Lig1/3 showed an effect on direct pGFP-1/pGFP-2 joining, while inhibition of PARP family proteins by Olaparib had no effect on DNA repair in this assay (Fig 5C) .
Induction of chromosomal deletions in the CLL cell line Mec1 is impaired upon inhibition of Lig1/3
Finally, we tested whether Lig1 or XRCC1/Lig3 is involved in the generation of chromosomal deletions between a 5'overhang DNA DSB and a blunt end DNA DSB in CLL. Therefore, we transiently transfected the CLL cell line Mec1 with constructs expressing TALENs (generating a 5'overhang) and Cas9 (generating blunt end DSBs), which both cleave at chromosome 17, with or without treatment with 30µM Lig1/3 inhibitor L67 (Fig 6A) . Of note, realtime RT-PCR revealed that in Mec1 cells, MMEJ specific factors Lig1, XRCC1 and PARP1 were also more abundantly expressed than in normal B cells (supplementary Fig S4) . We positively sorted transfected cells based on GFP expression from the Cas9 construct and estimated chromosomal deletion frequencies of a large 0.8Mb fragment by PCR on serially diluted input DNA isolated from sorted cells (Fig 6A, B) . As estimated from four independent experiments, the chromosomal deletion frequency of L67 treated cells was lower compared to untreated cells, as amplification of breakpoint junctions failed from 1.56ng input DNA of L67 treated cells in all experiments, whereas in two of four experiments, PCR amplified breakpoint junctions were detectable in untreated cells at that DNA concentration (Fig 6B) .
Amplicon sequencing of the PCR products from two experiments revealed that L67 treated
Mec1 cells had an increased frequency of short (5-49bp) deletions at the breakpoint junction, whereas large (≥50bp) deletions were reduced (Fig 6C) , again pointing to involvement of Lig1/3 in the occurrence of large deletions at repair joints. Small (0-4bp) deletions, likely resulting from direct joining or deletions within the 5' overhang were also reduced in L67 treated cells (Fig 6C) .
Thus, we infer that the described overexpression of Lig1 or XRCC1 in CLL could explain the observed bias towards both, MMEJ as well as increased repair of incompatible DNA ends with increased deletions at repair junctions.
Discussion
Aberrant repair of DSB can lead to genetic changes, driving carcinogenesis and clonal evolution of cancer. Here we describe several differences of DSB repair in B cells versus CLL 
DSB repair. This fits with the observation that chromosomal aberrations are frequently found to be subclonal in CLL, pointing to their successive generation during disease progression (6). In addition, an increased MMEJ activity could also explain the formation of small deletions and microdeletions frequently observed in CLL (44) and also in other cancer entities (45) . These deletions often exhibit sequence homologies at breakpoint junctions, suggesting that they likely arise due to MMEJ of DNA DSBs. Alternatively, they could occur by polymerase slippage during replication (46;47). As we observed several differences in end joining between CLL and B cells, it would be certainly interesting to screen DNA repair quality/quantity in therapy sensitive versus refractory samples as well as in other clinically relevant CLL subsets (such as samples with complex karyotype). Deriano and coworkers already reported increased error-prone end joining of DNA ends in CLL cells obtained from a therapy resistant patient (48) . Hence, it is conceivable that CLL subset or risk group specific differences in DNA DSB repair could contribute to diverse clinical outcomes.
Although a portion of CLL patients exhibits mutations at DNA repair genes (6), our data rather suggest an inherently aberrant DNA DSB repair activity in CLL due to different expression levels of key factors for MMEJ, in particular as we excluded del(11q) and del (17p) patients (harboring deleted ATM and p53 genes) and as all samples included in our analyses showed a very uniform pattern of repair junction formation, irrespective of the BCR mutation status.
Summarizing, we could identify profound differences in efficiency and precision of DSB 
usage of Lig1/3 inhibitors during CLL treatment would not only potentiate cytotoxicity of DNA damaging agents (50) but might also impede clonal evolution by acquisition of novel genomic rearrangements. 
